阿斯利康携重磅研究，创连续七年亮相美国临床肿瘤学会(asco)全体大会纪录，进一步彰显重新定义乳腺癌治疗和改变胃癌治疗结局的雄心-银河注册送38元

摘要标题

演示文稿详情  (cdt)

抗体偶联药物

shitara, k

trastuzumab deruxtecan (t-
dxd) vs ramucirumab (ram)
paclitaxel (ptx) in second-line
treatment of patients (pts) with
human epidermal growth factor
receptor 2-positive (her2 )
unresectable/metastatic gastric
cancer (gc) or
gastroesophageal junction
adenocarcinoma (geja):
primary analysis of the
randomized, phase 3
destiny-gastric04 study.

abstract #lba4002

oral abstract session

31 may 2025

3:24pm

tolaney, sm

trastuzumab deruxtecan (t-
dxd) pertuzumab (p) vs
taxane trastuzumab
pertuzumab (thp) for first-line
(1l) treatment of patients (pts)
with human epidermal growth
factor receptor 2–positive
(her2 ) advanced/metastatic
breast cancer (a/mbc): interim
results from destiny-breast09.

abstract #lba1008

oral abstract session

2 june 2025

7:30am

dent, r

exploratory biomarker analysis
of trastuzumab deruxtecan (t-
dxd) vs physician's choice of
chemotherapy (tpc) in her2-
low/-ultralow, hormone
receptor-positive (hr )
metastatic breast cancer (mbc)
in destiny-breast06 (db-06).

abstract #1013

oral abstract session

31 may 2025

3:23pm

levy, bp

tropion-lung02:
datopotamab deruxtecan
(dato-dxd) plus
pembrolizumab (pembro) with
or without platinum
chemotherapy (pt-ct) as first-
line (1l) therapy for advanced
non-small cell lung cancer (ansclc).

abstract #8501

oral abstract session

1 june 2025

8:12am

waqar, sn

first-line (1l) datopotamab
deruxtecan (dato-dxd)
rilvegostomig in advanced or
metastatic non-small cell lung
cancer (a/mnsclc): results
from tropion-lung04 (cohort 5).

abstract #8521 

poster session

31 may 2025

1:30pm

肿瘤驱动因素和耐药性

turner, nc

camizestrant cdk4/6
inhibitor (cdk4/6i) for the
treatment of emergent esr1
mutations during first-line (1l)
endocrine-based therapy (et)
and ahead of disease
progression in patients (pts)
with hr /her2– advanced
breast cancer (abc): phase 3,
double-blind ctdna-guided
serena-6 trial.

abstract #lba4

plenary session

1 june 2025

2:41pm

lu, s

savolitinib (savo) combined
with osimertinib (osi) versus
chemotherapy (chemo) in
egfr-mutant (egfrm) and
met-amplification (metamp)
advanced nsclc after disease
progression (pd) on egfr
tyrosine kinase inhibitor (tki):
results from a randomized
phase 3 sachi study.

abstract #lba8505

oral abstract session

1 june 2025

9:48am

levy, bp

efficacy and cns results from
a randomized subset of the
phase 2 savannah study
comparing savolitinib (savo)
osimertinib (osi) combination
with savo placebo (pbo).

abstract #8513

rapid oral abstract session

2 june 2025

8:06am

chaft je

neoadjuvant (neoadj)
osimertinib (osi) ±
chemotherapy (ct) vs ct
alone in resectable (r)
epidermal growth factor
receptor-mutated (egfrm)
nsclc: neoadaura.

abstract #8001

oral abstract session

2 june 2025

3:12pm

免疫肿瘤学与双特异性抗体

janjigian, yy

event-free survival in
matterhorn: a randomized,
phase 3 study of durvalumab
plus 5-fluorouracil, leucovorin,
oxaliplatin, and docetaxel
chemotherapy (flot) in
resectable
gastric/gastroesophageal
junction cancer (gc/gejc).

abstract #lba5

plenary session

1 june 2025

3:13pm

powles, t

circulating tumor dna (ctdna)
in patients with muscle-invasive
bladder cancer (mibc) who
received perioperative
durvalumab (d) in niagara

abstract #4503

oral abstract session

1 june 2025

10:45am

reck, m

associations of post-surgical
mrd status with neoadjuvant
ctdna dynamics, genomic
mutations, and clinical
outcomes in patients with
resectable nsclc (r-nsclc)
from the phase 3 aegean trial.

abstract #8009

rapid oral abstract session

1 june 2025

4:30pm

barbie, da

clinical and molecular
characteristics of early
progressors (eps) and long
-term progression-free survivors
(ltps) from the phase 3
adriatic trial of
consolidation durvalumab (d) vs placebo (p)
after concurrent
chemoradiotherapy (ccrt) in
limited-stage small-cell lung
cancer (ls-sclc).

abstract #8014

rapid oral abstract session

1 june 2025

5:12pm

mayadev, j

ultrasensitive detection and
tracking of circulating tumor
dna (ctdna) and association
with relapse and survival in
locally advanced cervical
cancer (lacc): phase 3
calla trial analyses.

abstract #5502

oral abstract session

2 june 2025

8:48am

westin, sn

durvalumab plus
carboplatin/paclitaxel followed
by durvalumab with or without
olaparib as first-line treatment
for endometrial cancer:
longitudinal changes in
circulating tumor dna.

abstract #5512

rapid oral abstract session

3 june 2025

8:30am

erinjeri, jp

outcomes by baseline tumor
burden using the 6-and-12
score in emerald-1: a phase
3 study of durvalumab (d) ±
bevacizumab (b) with transarterial
chemoembolization (tace) in
embolization-eligible
unresectable hepatocellular
carcinoma (uhcc).

abstract #4083
poster session

31 may 2025

9:00am

cascone, t

neoadjuvant durvalumab (d)
chemotherapy (ct) novel
anticancer agents and adjuvant
d ± novel agents in resectable
non-small-cell lung cancer
(nsclc): updated outcomes
from neocoast-2.

abstract #8046

poster session

31 may 2025

1:30pm

zhou, j

first-line rilvegostomig (rilve)
plus chemotherapy (ctx) in
advanced biliary tract cancer
(btc): primary analysis of
gemini-hepatobiliary substudy
2 cohort a.

abstract #4080

poster session

31 may 2025

9:00am

xu, r

artemide-gastric01: a phase
3 randomized study of
rilvegostomig with
fluoropyrimidine and
trastuzumab deruxtecan (t-
dxd) as first-line (1l) treatment
for locally advanced or
metastatic her2-positive
gastric or gastroesophageal
junction cancer (gc/gejc).

abstract #tps4204

poster session

31 may 2025

9:00am

mathias, c

artemide-lung03: a phase 3,
randomized, double-blind,
multicenter, global study of
rilvegostomig or
pembrolizumab in combination
with platinum-based
chemotherapy as first-line
treatment for patients with
metastatic non-squamous non-
small-cell lung cancer whose
tumors express pd-l1.

abstract #tps8653

poster session

31 may 2025

1:30pm

细胞疗法

yoo, c

rhea-1: first-in-human (fih)
study of azd9793, a first-in-
class cd8-guided t cell-
engager (tce) for glypican-3-
positive (gpc3 ) advanced or
metastatic hepatocellular
carcinoma (hcc).

abstract #tps4215

poster session

31 may 2025

9:00am

kim, tm

safety and efficacy of
azd0486, a cd19xcd3 t-cell
engager, in relapsed or
refractory diffuse large b-cell
lymphoma.

abstract #7046
poster session

1 june 2025

9:00am

shadman, m

titanium: an open-label,
global multicenter phase 1/2
study of azd5492, a first-in-
class subcutaneous cd8-
guided tri-specific t-cell
engager (tce), in patients (pts)
with relapsed or refractory (r/r)
b-cell malignancies.

abstract #tps7091

poster session

1 june 2025

9:00am

le gouill, s

soundtrack-e: a phase 1/2
open-label multicenter study to
evaluate the safety and
efficacy of azd0486
monotherapy or combination
therapy in patients with
mature b-cell malignancies.

abstract #tps7083

poster session

1 june 2025

9:00am

罕见病药物

chen, ap

efficacy and safety of
selumetinib in adults with
neurofibromatosis type 1 (nf1)
and symptomatic, inoperable
plexiform neurofibroma (pn):
primary analysis of komet
(nct04924608), a phase 3,
international, randomized,
placebo-controlled study.

abstract #3014

rapid oral abstract session

2 june 2025

8:00am